Article
Enhancing Wnt signaling lowers fracture incidence in a severe mouse model of Osteogenesis Imperfecta
2025-05-27
Abstract excerpt
Increased risk of fracture is a hallmark feature in the skeletal disorder Osteogenesis Imperfecta (OI). One therapy in clinical trials for OI is an antibody that neutralizes sclerostin (a Wnt signaling inhibitor) that is already FDA approved for patients with osteoporosis. In addition to increasing bone mass and lowering incident fractures in patients with osteoporosis, anti-sclerostin antibody increased bone mass...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 93f5feca-f6a9-5fc9-80dd-8b9b4cb8d653
- DOI
- 10.1101/2025.05.27.656429
